FDA Speeds Drug Checks with Pandemic-Inspired Alternative Tools Guidance
Published Date: 9/12/2025
Notice
Summary
The FDA just released new guidance to help drug makers and applicants understand how the agency will use alternative tools to check drug manufacturing facilities listed in their applications. This change speeds up reviews by using smart methods learned during the COVID-19 pandemic, affecting anyone submitting new drug or biologic applications. These updates start now and aim to make the process smoother without extra costs.
Analyzed Economic Effects
1 provisions identified: 1 benefits, 0 costs, 0 mixed.
FDA Uses Alternative Tools for Facility Checks
The FDA issued final guidance on how it will use alternative tools to assess drug manufacturing facilities named in marketing applications like NDAs, ANDAs, and BLAs (and supplements). The guidance finalizes the draft issued on September 22, 2023, implements best practices from tools used during the COVID-19 pandemic, and is now available to applicants. The document is tied to PDUFA VII and BsUFA III (Fiscal Years 2023 through 2027) and aims to make the review process smoother without extra costs.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2026-17215, Evaluation of Therapeutic Equivalence; Guidance for Industry; Availability
The Food and Drug Administration (FDA or Agency) is announcing the availability of a final guidance for industry titled "Evaluation of Therapeutic Equivalence." This guidance explains FDA's thinking on therapeutic equivalence evaluations and therapeutic equivalence codes (TE codes). FDA's therapeutic equivalence evaluations are listed for multisource prescription drug products approved under the Federal Food, Drug, and Cosmetic Act (FD&C Act) in the active section of the "Approved Drug Products With Therapeutic Equivalence Evaluations" (commonly known as the Orange Book). These therapeutic equivalence evaluations have been prepared to serve as public information and advice to state health agencies, prescribers, and pharmacists to promote public education in the area of drug product selection and to foster containment of health care costs. This guidance finalizes the draft guidance of the same title issued in July 2022.
2026-17229, Food and Drug Administration Modernization Act of 1997: Modifications to the List of Recognized Standards, Recognition List Number: 066
The Food and Drug Administration (FDA or the Agency) is announcing a publication containing modifications the Agency is making to the list of standards FDA recognizes for use in premarket reviews (FDA Recognized Consensus Standards). This publication, entitled "Modifications to the List of Recognized Standards, Recognition List Number: 066" (Recognition List Number: 066), will assist manufacturers who elect to declare conformity with consensus standards to meet certain requirements for medical devices.
2026-17222, Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability
The Food and Drug Administration (FDA or Agency) is announcing the availability of additional draft and revised draft product-specific guidances. The draft guidances provide product-specific recommendations on, among other things, the design of bioequivalence (BE) studies to support abbreviated new drug applications (ANDAs). In the Federal Register of June 11, 2010, FDA announced the availability of a guidance for industry titled "Bioequivalence Recommendations for Specific Products" that explained the process that would be used to make product-specific guidances available to the public on FDA's website. The draft guidances identified in this notice were developed using the process described in that guidance.
Previous / Next Documents
Previous: 2025-17697, Indian Gaming; Approval of the Snoqualmie Indian Tribe and the State of Washington Class III Gaming Compact Amendment
The Snoqualmie Indian Tribe and Washington State just got the green light to update their gaming deal! This update lets the tribe offer electronic table games, adding more fun options for players. The change boosts gaming choices and keeps the tribe and state working smoothly together.
Next: 2025-17708, Sunshine Act Meetings
The SEC’s Investor Advisory Committee is holding a public meeting on September 18, 2025, both in-person and online. This meeting invites the public to share their thoughts by September 17, 2025, and covers important topics like foreign companies and retail investors’ access to private markets. No new costs are involved, but it’s a great chance to join the conversation and stay in the loop!